• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Biotech (General)

Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead

Headed up by Scott Clarke, an ex-Roche exec who served as its global head of oncology partnering for Asia and emerging markets, the cancer immunotherapy company is working on several early assets, including TTX-030, a CD39-targeting antibody that last year attracted AbbVie’s interest and, according to preclinical data, seems to block an immune-inhibiting pathway in…

The CRA’s Guide to Monitoring Clinical Research

The guide that has trained thousands of CRAs is updated! The CRA’s Guide to Monitoring Clinical Research: A definitive resource for building mastery and complying with official regulations and guidelines. Use this guide to advance your career — plus ensure your trials follow critical requirements from FDA, ICH and NIH. In order to play a…

Novartis promises zero profit for 15 symptomatic COVID-19 drugs in low-income countries

Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way in the current fight. Novartis’ Sandoz unit will offer 15 generic and over-the-counter medicines at zero profit to developing countries during the pandemic, the company said Thursday. The portfolio covers widely used antibiotics and…

Imvax Inc. Raises $112 Million in Series C Financing

Imvax Inc. Raises $112 Million in Series C Financing Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme,  Phase 1 research into additional solid tumor indications and build out of the operational capabilities PHILADELPHIA, JULY 16, 2020 – Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being…

Here’s Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine

As of July 12, the number of new cases of COVID-19 in the U.S. has surpassed 60,000 for the fifth day in a row. Unfortunately, this rise cannot be attributed to increases in testing. For most of last week, nearly 1,000 Americans died each day due to COVID-19, representing a 300% increase from the death…

Brainstorm Cell Therapeutics : Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer’s Disease Program

NEW YORK, July 8, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader (KOL) webinar on its Alzheimer’s Disease (AD) program today at 8:15 AM Eastern Time. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn® and begin…

200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy

Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, a cell-based therapy for people with amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics, the therapy’s developer, announced. The Phase 3 trial (NCT03280056), which enrolled about 200 participants, is underway at six U.S. sites: the University of California, Irvine; Cedars-Sinai Medical Center; California Pacific Medical Center; Massachusetts General Hospital;…

BrainStorm to Showcase Alzheimer’s Disease Clinical Program in KOL Webinar

NEW YORK, July 1, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key Opinion Leader (KOL) webinar on the Company’s Alzheimer’s disease (AD) clinical program on Wednesday July 8th at 8.15am ET. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn®…

Cannabis Companies Eyeing How Plant Could Help Autism Symptoms

After seeing some success around a treatment for epilepsy, the cannabis industry is increasingly eyeing for products for people with the autism spectrum disorder. Autism is a lifelong developmental disorder that affects communication, behavior and the ability to socialize. As many as one in 54 children are currently diagnosed with autism, according to Centers for Disease Control, and so are millions of adults. In addition…

BrainStorm to study stem cell treatment in Alzheimer’s patients

TEL AVIV (Reuters) – BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer’s disease. The U.S.-Israeli company is already conducting advanced trials of its treatment called NurOwn in patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). MORE…